Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results